medigraphic.com
Órgano Oficial de la Asociación Mexicana de Infectología Pediátrica y la SLIPE.

2007, Number 80

<< Back Next >>

Rev Enfer Infec Pediatr 2007; 20.21 (80)

Clinical features and risk factors for Burkholderia cepacia bacteremia in children

Cardoso HG, De Colsa RA, Zepeda OG, Arzate BP, González SN

Language: Spanish
References: 29
Page: 92-98
PDF size: 76.91 Kb.


ABSTRACT

Introduction: Burkholderia cepacia is being recognized more often as etiologic agent of nosocomial bacteremia (NB) in children. Our objective is to describe the clinical and laboratory features, and possible risk factors for the development of hospital-acquired B. cepacia bacteremia in a period of five years. Methods: case control study, comparison of 80 B. cepacia NB vs 80 control. We analyzed clinical and laboratory features, risk factors, antimicrobial susceptibility pattern and outcome of the patients. Results: there are no clinical or laboratory specific features for this agent. Most of the isolates were susceptible to cotrimoxasol (93.7%) and meropenem (91.2%), less than half were susceptible to ceftazidime (47.5%), imipenem (38.7%), and ciprofloxacin (18.7%). Moreover, 50% of the patients were hospitalized in an intensive care unit, severely ill and submitted to at least one invasive procedure; 74 patients (84.5%) had a favorable outcome; the mortality rate was 7.5%. Conclusions: B. cepacia bacteremia is a nosocomial-acquired infection, affecting severely ill patients that undergo invasive procedures for diagnostic or therapeutic means. The frequency in our hospital is low, but is life-threatening and increases substantially hospital stay and cost. For being an opportunistic microorganism of difficult treatment, with resistance to multiple antibiotics; the opportune treatment, depending on the patterns of susceptibility of each institution, improves the outcome of the patient with increased survival possibilities.


REFERENCES

  1. Burkholder W. Sour skin a bacteria rot of onion bulbs. Phytopathology 1950; 40:115-8.

  2. Pegues DA, Carson LA, Anderson RL, Norgard MJ, Argent TA, Jarvis WR, et al. Outbreak of Pseudomonas cepacia bacteremia in oncology patients. Clin Infect Dis 1993; 16: 407-11.

  3. Shehabi AA, Abu-Al-Soud W, Mahafzah A, Khuri-Bulos N, Abu Khader I, Ouis IS, et al. Investigation of Burkholderia cepacia nosocomial outbreak with high fatality in patients suffering from diseases other than cystic fibrosis. Scand J Infect Dis 2004; 36:174-8.

  4. Govan JR, Hughes JE, Vandamme P. Burkholderia cepacia: medical, taxonomic and ecological issues. J Med Microbiol 1996;45:395-407.

  5. Mortensen JE, Fisher MC, LiPuma JJ. Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment. Infect Control Hosp Epidemiol 1995;16:30-2.

  6. Pallet LJ, Hugo WB, Grant DWJ. Pseudomonas cepacia as a contaminant and infective agent. J Hosp Infect 1983;4:9-13.

  7. Mangram A, Jarvis WR. Nosocomial Burkholderia cepacia outbreaks and pseudo-outbreaks. Infect Control Hosp Epidemiol 1996;17:718-20.

  8. Pujol M, Corbell X, Carratala J, et al. Community-acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host. Clin Infect Dis 1992;15:887-888.

  9. Goldmann DA, Klinger JD. Pseudomonas cepacia: biology, mechanisms of virulence, epidemiology. J Pediatr 1986;108:806-12.

  10. Moles A, Notan R, Taylor R, Finley R, Riley M, Ru-zhang J, et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999;179:1197-1205.

  11. Tablan O, Chorba T, Schildlow D. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985;107:382-7.

  12. Kahyaoglu O, Nolan B, Kumar A. Burkholderia cepacia sepsis in neonatos. Pediatr Infect Dis J 1995;14:815-816.

  13. Brauner A, Hoiby N, Kjartansson J, Kuhn I, Svenberg-Appelgren P, Wretlind B. Pseudomonas cepacia septicaemia in patients with burns: Report of two cases. Scand J infect Dis 1985;17:63-66.

  14. Yamagishi Y, Fujita J, Takigawa K, Nakazawa T, Takahara J. Clinical feature of Pseudomonas cepacia pneumonia in a epidemic among immunocompromised patients. Chest 1993;1003:1706-09.

  15. Doit C, Loukil C, Simon AM, Ferroni A, Fontan JE, Bonacorsi S, et al. Outbreak of Burkholderia cepacia bacteremia in a pediatric hospital due to contamination of lipid emulsion stoppers. J Clin Microbiol 2004;42:2227-30.

  16. Lu DC, Chang SC, Chen YC, Luh KT, Lee CY, Hsieh WC. Burkholderia cepacia bacteremia: a retrospective analysis of 70 episodes. J Formos Med Assoc 1997;96:972-8.

  17. Huang CH, Jang TN, Liu CY, Fung CP, Yu KW, Wong WW. Characteristics of patients with Burkholderia cepacia bacteremia. J Microbiol Immunol Infect 2001;34:215-9.

  18. Yu WL, Wang DY, Lin CW, Tsou MF. Endemic Burkholderia cepacia bacteraemia: clinical features and antimicrobial susceptibilities of isolates. Scand J Infect Dis 1999;31: 293-8.

  19. Woods CW, Bressler AM, Lipuma JL, Alexander BD, Clements DA, Weber DJ, et al. Virulence associated with outbreak-related strains of Burkholderia cepacia complex among a cohort of patients with bacteremia. Clin Infect Dis 2004;38:1243-50.

  20. NCCLS. Quality Assurance for Commercially Prepared Microbiological Culture media. Approved standars. 2nd ed. Document M22-A2. Wayne P: NCCLS, 1996.

  21. NCCLS. Perfrormance Standars for Antimicrobial Susceptibility Testing. Document M100-S13. Wayne P: NCCLS, 2003.

  22. Center for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter related infections. MMWR August 9, 2002; 51(RR-10):1-32.

  23. Goldstein B, Giroir B, Randolph A. International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005;6:2-8.

  24. See LL. Bloodstream infection in children. Pediatr Crit Care Med 2005;6(3 Suppl):S42-4.

  25. Tomich M, Herfst CA, Golden JW, Mohr CD. Role of flagella in host cell invasion by Burkholderia cepacia. Infect Immun 2002;70:1799-806.

  26. Bhakta DR, Leader I, Jacobson T, Robinson-Dun B, Honicky RE, Kumar A. Antibacterial properties of investigational, new, and commonly used antibiotics against isolates of Pseudomonas cepacia in Michigan. Chemotherapy 1992;38:319-23.

  27. Fass RJ, Barnishan J, Solomon MC, Ayers LW. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother 1996;40:1412-8.

  28. Rajyaguru JM, Muszynski MJ. Association of resistance to trimethoprim/ sulphamethoxazole, chloramphenicol and quinolones with changes in major outer membrane proteins and lipopolysaccharide in Burkholderia cepacia. J Antimicrobial Chemotherapy 1997; 40:803-809.

  29. Kazunobu O, Mituko A, Mikio K, Toyoko O, Jun I, Teruko N. Analysis of Strains of Burkholderia (Pseudomonas) cepacia. Isolated in a Nosocomial Outbreak by Biochemical and Genomic Typing. J Clin Microbiol 1995; 33:2353-2357.




2020     |     www.medigraphic.com